Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

NCT01560416 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Fulvestrant
DRUG: Ganetespib

Sponsor

Dana-Farber Cancer Institute